Hormone Therapy

CHICAGO — It is important for clinicians to realize that there are many barriers to a person’s gender transition, Jennifer L. MacGregor, MD, said here at the American Society for Dermatologic Surgery annual meeting.

Longer endogenous estrogen exposure and use of hormone therapy are associated with higher cognitive status in late life, especially among older women when compared with younger women, according to findings published in Menopause.

Women who had premature and early menopause had an increased risk for a nonfatal CVD event before age 60 years compared with those who had menopause from age 50 to 51 years, according to a pooled analysis published in The Lancet Public Health.

Young adults born small for gestational age treated with long-term growth hormone therapy had stable renal function in the 5 years after stopping treatment, with an estimated glomerular filtration rate comparable to healthy controls and young adults with short stature who did not receive GH, according to findings published in Clinical Endocrinology.

Among Danish women with Turner syndrome, those prescribed hormone therapy were less likely to develop diabetes, sustain an osteoporotic fracture or be hospitalized for stroke during nearly 4 decades of follow-up when compared with those not prescribed HT, according to findings published in The Journal of Clinical Endocrinology & Metabolism.

Pellet hormone therapy, a solid custom-compounded bioidentical estrogen therapy that is inserted under the skin, may be less safe than FDA-approved HT therapies for postmenopausal women, according to findings presented at the North American Menopause Society annual meeting.

Transgender adolescents prescribed gender-affirming hormone therapy have substantial differences in body composition when compared with cisgender youths, with body fat and lean mass measurements intermediate between BMI-matched cisgender males and females, according to findings published in The Journal of Clinical Endocrinology & Metabolism.

Hormone therapy may slow the development of diabetes among postmenopausal women due to its effects on certain metabolites, according to findings presented at the North American Menopause Society annual meeting.

Estradiol levels among early and late postmenopausal women taking hormone therapy are influenced by several clinical and lifestyle factors, including BMI, surgical menopause, smoking, alcohol use and antifungal medication use, according to findings presented at the North American Menopause Society annual meeting.

A Dutch cohort of older transgender women prescribed long-term gender-affirming hormone therapy had a 3-year fracture risk that was comparable to that of cisgender women, according to findings published in the Journal of Bone and Mineral Research.